A Multi-Center Randomized Double Blind Placebo-Controlle

Project: Research project

Project Details

Description

A Multi-Center Randomized Double Blind Placebo-Controlled Phase III trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Theraapy following Allogeneic Transplant for patients with FLT3-ITD AML
StatusActive
Effective start/end date5/1/175/30/22

Funding

  • National Marrow Donor Program

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.